Pravastatin

Generic Name
Pravastatin
Brand Names
-
Drug Type
Small Molecule
Chemical Formula
C23H36O7
CAS Number
81093-37-0
Unique Ingredient Identifier
KXO2KT9N0G
Background

Pravastatin is the 6-alpha-hydroxy acid form of mevastatin. Pravastatin was firstly approved in 1991 becoming the second available statin in the United States. It was the first statin administered as the active form and not as a prodrug. This drug was developed by Sankyo Co. Ltd.; however, the first approved pravastatin product was developed by Bristol Myers...

Indication

Pravastatin is indicated for primary prevention of coronary events hypercholesterolemic patients without clinical evidence of coronary heart disease. Its use includes the reduction of risk on myocardial infarction, undergoing myocardial revascularization procedures and cardiovascular mortality.
...

Associated Conditions
Acute Coronary Events, Cardiovascular Outcomes, Coronary Artery Atherosclerosis, Death, Dysbetalipoproteinemia, Heterozygous Familial Hypercholesterolemia (HeFH), High Cholesterol, Hyperlipidemias, Mixed Dyslipidemias, Myocardial Infarction, Myocardial Revascularization, Secondary prevention cardiovascular event, Stroke, Sudden Cardiac Death, Transient Ischemic Attack, Elevation of serum triglyceride levels
Associated Therapies
-
Clinical Trials
Related News

StAT-TB (Statin Adjunctive Therapy for TB): A Phase 2b Dose-finding Study of Pravastatin in Adults With Tuberculosis

First Posted Date
2019-03-20
Last Posted Date
2023-09-18
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Target Recruit Count
16
Registration Number
NCT03882177
Locations
🇿🇦

PHRU Non-Network CRS, Johannesburg, Gauteng, South Africa

Drug-Drug Interaction Study of Vadadustat With Rosuvastatin, Sulfasalazine, Pravastatin, Atorvastatin and Simvastatin

First Posted Date
2019-01-11
Last Posted Date
2019-03-22
Lead Sponsor
Akebia Therapeutics
Target Recruit Count
134
Registration Number
NCT03801733
Locations
🇨🇦

InVentiv Health Clinique Inc., Québec City, Quebec, Canada

Indonesia Pravastatin to Prevent Preeclampsia Study

Phase 2
Conditions
Pre-Eclampsia
Interventions
Drug: Pravastatin
First Posted Date
2018-08-28
Last Posted Date
2018-08-28
Lead Sponsor
Universitas Airlangga
Target Recruit Count
280
Registration Number
NCT03648970
Locations
🇮🇩

Adam Malik General Hospital, Medan, North Sumatra, Indonesia

🇮🇩

Dr. Wahidin Sudirohusodo General Hospital, Makasar, South Sulawesi, Indonesia

🇮🇩

Hasan Sadikin General Hospital, Bandung, West Java, Indonesia

and more 4 locations

An Efficacy and Safety Study of Alirocumab in Children and Adolescents With Heterozygous Familial Hypercholesterolemia

First Posted Date
2018-04-27
Last Posted Date
2023-05-06
Lead Sponsor
Sanofi
Target Recruit Count
153
Registration Number
NCT03510884
Locations
🇪🇸

Investigational Site Number :7240003, Pamplona, Navarra, Spain

🇵🇱

Investigational Site Number :6160002, Gdansk, Pomorskie, Poland

🇲🇽

Investigational Site Number :4840007, Oaxaca, Mexico

and more 40 locations

An Efficacy and Safety Study of Alirocumab in Children and Adolescents With Homozygous Familial Hypercholesterolemia

First Posted Date
2018-04-27
Last Posted Date
2020-12-29
Lead Sponsor
Sanofi
Target Recruit Count
18
Registration Number
NCT03510715
Locations
🇩🇰

Investigational Site Number 2080001, Viborg, Denmark

🇪🇸

Investigational Site Number 7240001, A Coruna, Spain

🇸🇮

Investigational Site Number 7050001, Ljubljana, Slovenia

and more 7 locations

Statin Adjunctive Therapy for TB

Phase 2
Completed
Conditions
Tuberculosis
Interventions
Drug: Pravastatin
First Posted Date
2018-03-07
Last Posted Date
2023-06-28
Lead Sponsor
Johns Hopkins University
Target Recruit Count
16
Registration Number
NCT03456102
Locations
🇿🇦

Chris Hani Baragwanath Hospital, Johannesburg, South Africa

Statin Therapy in Patients With Early Stage ADPKD

Phase 4
Active, not recruiting
Conditions
Autosomal Dominant Polycystic Kidney
ADPKD
Interventions
Drug: Placebo
Drug: Pravastatin
First Posted Date
2017-09-06
Last Posted Date
2024-04-10
Lead Sponsor
University of Colorado, Denver
Target Recruit Count
150
Registration Number
NCT03273413
Locations
🇺🇸

University of Colorado Denver Anschutz Medical Campus, Denver, Colorado, United States

Effects of Concomitant Administration of BMS-986195 on Methotrexate, Caffeine, Montelukast, Flurbiprofen, Omeprazole, Midazolam, Digoxin, and Pravastatin

First Posted Date
2017-04-27
Last Posted Date
2017-12-15
Lead Sponsor
Bristol-Myers Squibb
Target Recruit Count
26
Registration Number
NCT03131973
Locations
🇺🇸

PPD Development, LP, Austin, Texas, United States

Prevention of Renal and Vascular Endstage Disease Intervention Trial

First Posted Date
2017-03-08
Last Posted Date
2017-03-10
Lead Sponsor
University Medical Center Groningen
Target Recruit Count
864
Registration Number
NCT03073018

Effect of Pravastatin on Erythrocyte Membrane Fatty Acid Contents in Patients With Chronic Kidney Disease

Phase 4
Completed
Conditions
Chronic Kidney Disease
Interventions
Drug: Pravastatin
First Posted Date
2016-12-14
Last Posted Date
2019-03-11
Lead Sponsor
Dong-A University
Target Recruit Count
62
Registration Number
NCT02992548
Locations
🇰🇷

Inje University, Pusan Paik Hospital, Busan, Korea, Republic of

🇰🇷

Dong-A University, Busan, Korea, Republic of

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy